BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is one of the most common disorders of the liver worldwide. Recently, a correlation between thyroid dysfunction and NAFLD has been discussed. Objective of the present study was to investigate the association between thyroid dysfunction and hepatic steatosis. METHODS Data from 2,445 subjects (51.7% females) aged 18 to 65 years participating ...

BACKGROUND In chronic hepatitis C, it has been suggested that steatosis could accelerate progression of fibrosis. However, results of the few published studies are controversial. AIM To determine the characteristics (epidemiological, biological, and histological) associated with steatosis and its relationship with liver lesions (grade of necroinflammation and stage of fibrosis) in patients wi...

OBJECTIVE Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepatic steatosis. We hypothesized that suppression of lipogenesis, which is pathologically elevated i...

BACKGROUND Several common metabolic risk factors contribute to development of both non-alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD). The aim was to determine prevalence of NAFLD in patients with CAD. METHODS This prospective study was carried out from December 2011 to June 2012. All patients with documented diagnosis of CAD with stenosis of one of the main coronary ...

BACKGROUND Steatosis is common in patients with hepatitis C virus (HCV) infection and may be a major determinant of progression of liver injury. This study evaluated FibroMax™ for noninvasive diagnosis of steatosis in patients with chronic HCV. METHODS This cross-sectional study included 44 patients naïve to treatment who were referred to our hepatology clinic for assessment of fitness for an...

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is currently conceptualised as a clinical spectrum that results from a ‘multiple-hit’ process which begins with simple steatosis and subsequently renders the hepatocytes susceptible to a variety of insults. Ultimately, more serious liver injuries like non-alcoholic steatohepatitis (NASH) and cirrhosis may develop. Although the metabolic syndr...

Valproic acid (VPA) is a widely prescribed antiepileptic drug in the world. Despite its pharmacological importance, it may cause liver toxicity and steatosis. However the exact mechanism of the steatosis formation is unknown. The data presented in this DIB publication is used to further investigate the VPA-induced mechanisms of steatosis by analyzing changes in patterns of methylation. Therefor...

Concomitant steatosis in chronic hepatitis C is associated with fibrosis and unfavorable treatment outcome. Central zone injury in nonalcoholic steatohepatitis (NASH) manifests as central portalization, with centrizonal microvessels and ductular reaction. We investigated whether central portalization in steatotic HCV biopsies would identify patients with metabolic risk factors for NASH. Liver b...

UNLABELLED In this paper we discuss the problem of computer aided evaluation of the severity of steatosis disease using ultrasound images. The AIM of the study being to compare the automatic evaluation of liver steatosis using random forests (RF) and support vector machine (SVM) classifiers. MATERIAL AND METHOD One hundred and twenty consecutive patients with steatosis or normal liver, assess...

Background: Integrins are transmembrane mechanosensitive proteins that negatively contribute to the pathogenesis of different types chronic liver disease and can activate focal adhesion kinase (FAK). Objectives: This study aimed determine hepatic integrin β1 FAK mRNA as well transcriptional coactivator with PDZ-binding motif (TAZ) protein expressions in cirrhotic patients simple steatosis. Meth...